The type II inositol 3,4-bisphosphate 4-phosphatase (INPP4B) is a recently identified tumor suppressor modulating the PI3K/Akt signaling pathway. Mechanistically, INPP4B hydrolyzes phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) to regulate phosphorylation and cytoplasmic activation of Akt. Loss or silenced INPP4B expression was associated with increased activated Akt and anchorage-independent growth.
INPP4B expression has been evaluated in breast, ovarian and prostate cancers. Immunohistochemical studies using tumor tissues and tissue microarrays demonstrated significantly reduced expression in cancer cells compared with benign tissue. In gene expression studies, INPP4B RNA levels were decreased in 8% of clinically localized, and 47% of metastatic disease. In breast cancer, loss of INPP4B occurs most frequently in aggressive hormone receptor-negative basal-like breast carcinomas, with higher tumor grade and size. Diminished INPP4B levels are correlated with poor outcomes and reduced recurrence-free survival.
Literature:
Manufacturer site:
INPP4B (EP328)
Rabbit Monoclonal
The type II inositol 3,4-bisphosphate 4-phosphatase (INPP4B) is a recently identified tumor suppressor modulating the PI3K/Akt signaling pathway. Mechanistically, INPP4B hydrolyzes phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) to regulate phosphorylation and cytoplasmic activation of Akt. Loss or silenced INPP4B expression was associated with increased activated Akt and anchorage-independent growth.
INPP4B expression has been evaluated in breast, ovarian and prostate cancers. Immunohistochemical studies using tumor tissues and tissue microarrays demonstrated significantly reduced expression in cancer cells compared with benign tissue. In gene expression studies, INPP4B RNA levels were decreased in 8% of clinically localized, and 47% of metastatic disease. In breast cancer, loss of INPP4B occurs most frequently in aggressive hormone receptor-negative basal-like breast carcinomas, with higher tumor grade and size. Diminished INPP4B levels are correlated with poor outcomes and reduced recurrence-free survival.
Rabbit Monoclonal
The type II inositol 3,4-bisphosphate 4-phosphatase (INPP4B) is a recently identified tumor suppressor modulating the PI3K/Akt signaling pathway. Mechanistically, INPP4B hydrolyzes phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) to regulate phosphorylation and cytoplasmic activation of Akt. Loss or silenced INPP4B expression was associated with increased activated Akt and anchorage-independent growth.
INPP4B expression has been evaluated in breast, ovarian and prostate cancers. Immunohistochemical studies using tumor tissues and tissue microarrays demonstrated significantly reduced expression in cancer cells compared with benign tissue. In gene expression studies, INPP4B RNA levels were decreased in 8% of clinically localized, and 47% of metastatic disease. In breast cancer, loss of INPP4B occurs most frequently in aggressive hormone receptor-negative basal-like breast carcinomas, with higher tumor grade and size. Diminished INPP4B levels are correlated with poor outcomes and reduced recurrence-free survival.
